The company said revenue for Q3 rose 18% to $95.3 billion on December 31, 2024, citing higher prescription volumes in the U.S. Pharmaceutical segment and growth in the oncology platform as the main drivers.

1. 01

   The company said revenue for Q3 rose 18% to $95.3 billion on December 31, 2024, citing higher prescription volumes in the U.S. Pharmaceutical segment and growth in the oncology platform as the main drivers.

2. 02

   McKesson said diluted earnings per share for Q3 were $6.95 ($4.42 a year earlier), and Adjusted Earnings per Diluted Share were $8.03 ($7.74 a year earlier), an increase of 4%. The company cited the prior-year increase in the provision for bad debts related to the Rite Aid bankruptcy as a factor in the GAAP increase.

3. 03

   The company said it raised and narrowed its fiscal 2025 Adjusted Earnings per Diluted Share guidance to $32.55 to $32.95 from the prior range of $32.40 to $33.00, and that it does not provide GAAP earnings per diluted share outlook.

4. 04

   McKesson said it used cash from operations of $1.7 billion in the first 9 months of its fiscal year and spent $581 million on capital expenditures, resulting in negative Free Cash Flow of $2.2 billion. The company also said it repurchased $2.8 billion of common stock and paid $254 million in dividends over the same period.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.